Page 6 - Beyond Human News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Noah Media Group has released a trailer (watch it below) for the 60-minute triathlon documentary Beyond Human. It’s producing the documentary for the Professional Triathletes Organisation (PTO). The film follows triathletes as they prepare for the PTO’s flagship event, The Collins Cup – a rivalry fuelled, Ryder Cup-style format. The aim is to bring out the excitement, rivalry, drama and personalities of the sport, to help attract a wider fan base. The documentary features triathletes Lionel Sanders (Canada), Sebastien Kienle (Germany) and Heather Jackson (USA), who give the Noah product...

Aytu BioScience, Inc.: Aytu BioScience to Present at Upcoming March Investor Conferences ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: Cowen 41 st Annual Healthcare Conference: A live virtual presentation will occur on Wednesday, March 3, 2021 at 10:20 a.m. ET. H.C. Wainwright Global Life Sciences Conferenc...

(2) Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / February 4, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal second quarter ended December 31, 2020 on February 11, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provide an overview of its business and growth strategy. Conference Call Information 201-689-8584 (interna...

(2) ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriter's option to purchase an additional 625,000 shares of common stock, at a price to the public of $6.00 per share. H.C. Wainwright & Co. acted as the sole book-running manager for...

Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos' established,